Trials / Withdrawn
WithdrawnNCT04106076
Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia
Phase I, Open Label Dose-escalation Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of Multiple Infusions of UCART123 (Allogeneic Engineered T-cells Expressing Anti-CD123 Chimeric Antigen Receptor) in Patients With Adverse Genetic Risk Acute Myeloid Leukaemia
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Cellectis S.A. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I, open-label, dose escalation study of UCART123 administered intravenously to patients with newly diagnosed CD123 positive adverse genetic risk acute myeloid leukaemia (AML) defined in the ELN adverse genetic risk group (2017). The purpose of this study is to evaluate the safety and clinical activity of multiple infusions of UCART123 and to determine the Maximum Tolerated Dose (MTD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | UCART123 | Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor |
Timeline
- Start date
- 2019-07-11
- Primary completion
- 2019-12-05
- Completion
- 2019-12-05
- First posted
- 2019-09-26
- Last updated
- 2020-07-14
Source: ClinicalTrials.gov record NCT04106076. Inclusion in this directory is not an endorsement.